Teva’s Biosimilar Capabilities Mount with its Latest Joint Venture
By Sally Mardikian PhD
Pharma Deals Review: Vol 2009 Issue 1 (Table of Contents)
Published: 20 Jan-2009
DOI: 10.3833/pdr.v2009.i1.90 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
Teva’s biosimilar development expertise is set to increase with its latest joint venture with Swiss company, Lonza...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS